Award

Real-world Benefits and Harms of Spironolactone in Adults with Resistant Hypertension: A Target Trial Emulation

Description: Resistant hypertension (RH), defined as persistent high blood pressure despite treatment with three anti-hypertensive medications, affects 10-20% of hypertensive patients and significantly increases the risk of cardiovascular and kidney disease. While the 2017 AHA/ACC guidelines recommend a fourth-line drug for treating RH, the optimal choice remains unclear. The Prevention and Treatment of Hypertension with Algorithm-based Therapy 2 (PATHWAY-2) trial found spironolactone to be the most effective fourth-line therapy for blood pressure control in RH patients compared to an alpha or beta blocker. However, it was not representative of patients with frailty, diabetes, chronic kidney disease, or older age, who are more vulnerable to adverse treatment effects. Therefore, the favorable risk-benefit profile of spironolactone observed in PATHWAY-2 may not extend to the broader population. Prior studies have also not been adequately powered to study long-term clinical outcomes. We will use target trial emulation, a novel modern causal inference method, to evaluate the comparative benefits and risks of spironolactone to other fourth-line therapies in real-world RH patients using data from the Veterans Health Administration and Kaiser Permanente Southern California. We aim to estimate the effect of adding spironolactone versus an alpha or beta blocker on 1) blood pressure control, and 2) the risk for death, cardiovascular, kidney, and serious adverse events in patients with RH. We will assess subgroup effects by age, frailty, diabetes status, and kidney function. We hypothesize that spironolactone will reduce risks for death, cardiovascular, and kidney events, but increase the risk for serious adverse events; effects will differ by subgroup. Our findings will inform RH treatment decisions, and assess the risk-benefit profile of spironolactone treatment in groups at high risk for adverse outcomes. This fellowship will also support the career development of Ms. June Li, a doctoral student in the Department of Epidemiology and Population Health at Stanford School of Medicine. Through the proposed research, the applicant will pursue training in causal inference methods, translating clinical findings to broader populations, and treatment of cardiovascular and kidney disease, supported by an experienced mentorship team. This fellowship will allow the applicant to develop skills that further establishes her as independent researcher in cardiovascular and kidney disease.
Amount: $69,550
Funding type: training
Funder scheme: Predoctoral Fellowship
Start date: 2025-01-01
End date: 2026-12-31
Investigator: June Li (lead)
Institutions: Stanford University, The Board of Trustees of the Leland Stanford Junior University
Field: Medicine
Funded outputs count: 0
Funder award ID: 25PRE1361733
OpenAlex ID: G2390457876